SVB Leerink Analysts Reduce Earnings Estimates for Moderna, Inc. (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNAGet Rating) – Investment analysts at SVB Leerink reduced their Q3 2022 earnings per share (EPS) estimates for Moderna in a report released on Thursday, August 4th. SVB Leerink analyst M. Foroohar now anticipates that the company will earn $5.45 per share for the quarter, down from their previous forecast of $5.68. SVB Leerink currently has a “Underperform” rating and a $77.00 target price on the stock. The consensus estimate for Moderna’s current full-year earnings is $27.29 per share. SVB Leerink also issued estimates for Moderna’s FY2023 earnings at $7.83 EPS and FY2024 earnings at $4.05 EPS.

Moderna (NASDAQ:MRNAGet Rating) last released its earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.73 by $0.51. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The business had revenue of $4.73 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the company posted $6.46 earnings per share. Moderna’s revenue was up 8.7% on a year-over-year basis.

Several other research firms have also issued reports on MRNA. Piper Sandler dropped their target price on Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a report on Tuesday, May 17th. Morgan Stanley dropped their price objective on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research note on Thursday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $226.92.

Moderna Stock Performance

MRNA opened at $186.84 on Friday. Moderna has a 52-week low of $115.61 and a 52-week high of $497.49. The firm has a market capitalization of $74.32 billion, a PE ratio of 5.69, a PEG ratio of 1.05 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.99. The business’s 50-day simple moving average is $152.33 and its 200 day simple moving average is $152.85.

Institutional Investors Weigh In On Moderna

A number of large investors have recently added to or reduced their stakes in the stock. Allworth Financial LP boosted its holdings in shares of Moderna by 3.5% in the 2nd quarter. Allworth Financial LP now owns 1,780 shares of the company’s stock valued at $254,000 after purchasing an additional 60 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Moderna by 20.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 371 shares of the company’s stock valued at $53,000 after purchasing an additional 62 shares in the last quarter. AlphaMark Advisors LLC boosted its holdings in shares of Moderna by 18.2% in the 4th quarter. AlphaMark Advisors LLC now owns 415 shares of the company’s stock valued at $105,000 after purchasing an additional 64 shares in the last quarter. PFG Private Wealth Management LLC boosted its holdings in shares of Moderna by 4.5% in the 2nd quarter. PFG Private Wealth Management LLC now owns 1,547 shares of the company’s stock valued at $221,000 after purchasing an additional 66 shares in the last quarter. Finally, Kalos Management Inc. boosted its holdings in shares of Moderna by 7.9% during the 4th quarter. Kalos Management Inc. now owns 927 shares of the company’s stock valued at $219,000 after acquiring an additional 68 shares in the last quarter. Institutional investors and hedge funds own 61.20% of the company’s stock.

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 10,000 shares of the stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $123.00, for a total transaction of $1,230,000.00. Following the transaction, the president now owns 1,624,231 shares in the company, valued at $199,780,413. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, President Stephen Hoge sold 10,000 shares of the stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $123.00, for a total transaction of $1,230,000.00. Following the sale, the president now owns 1,624,231 shares of the company’s stock, valued at $199,780,413. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Noubar Afeyan sold 100,000 shares of the stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $134.47, for a total value of $13,447,000.00. Following the sale, the director now directly owns 5,816,657 shares in the company, valued at approximately $782,165,866.79. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 606,029 shares of company stock worth $91,997,025. Company insiders own 17.30% of the company’s stock.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Want More Great Investing Ideas?

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.